Clinical Trials Logo

Clinical Trial Summary

Blind, placebo-controlled study testing the hypothesis that oral dietary supplement rich with fucoxanthin will decrease biochemical clinical markers related to liver health.


Clinical Trial Description

Six month supplementation ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03625284
Study type Interventional
Source Algatechnologies Ltd.
Contact Tair Lapidot, Dr
Phone +972548095209
Email tair@algatech.com
Status Not yet recruiting
Phase N/A
Start date September 10, 2018
Completion date December 10, 2019

See also
  Status Clinical Trial Phase
Completed NCT02923804 - Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients N/A
Completed NCT03222206 - The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Phase 4
Completed NCT04823676 - Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management N/A
Completed NCT03186859 - Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease) N/A
Completed NCT02030977 - The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis Phase 2/Phase 3
Recruiting NCT06176079 - Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
Not yet recruiting NCT06138821 - ESG vs GLP-1RA vs ESG + GLP-1RA in Patients With Obesity, NAFLD and Advanced Fibrosis: A Randomized Controlled Trial Phase 4
Not yet recruiting NCT04553796 - Assessment of Nonalcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Noninvasive Methods.
Not yet recruiting NCT03801577 - Hepaxa Management of Non-alcoholic Fatty Liver Disease N/A
Completed NCT05804422 - Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study) N/A
Recruiting NCT04625166 - Combi-elastography Assessment of Chronic Liver Disease Multi-center Study
Recruiting NCT05523024 - Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL. N/A
Not yet recruiting NCT05822622 - Relationship Between Heart Failure With Preserved Ejection Fraction and Nonalcoholic Fatty Liver Disease.